Citations

Clear

3057 citation(s) found for "Cd, Johnson".

The use and safety of peripheral intravenous catheters (PIV) vs central venous catheters (CVC) for lymphoma patients receiving frontline anthracycline-based chemotherapy: A large multicenter real-world analysis (RWA)
Glennan, Patrick, Nedved, Adrienne, Lukowski, Joseph , Minhaj, Adeeb A., Sanjurjo, Alexander , Harbhajan, Melinda, Norrell, Jacqueline , Mubeen, Suhaym , St‐Pierre, Frédérique , Kindl, Gabriel, Patel, Keem, Adewale, Olutobi, Allen, Harris, Luyten, Sophia, Dasari, Srilatha, Martin, Peter W., Lunning, Matthew A. , Nowakowski, Grzegorz S. , Tiger, Yun Kyoung , Sanjurjo, Alexander Daniel , Mubeen, Salmaan, Kindl, Gabriel, Adewale, Olutobi, Allen, Harris, Omer, Zulfa , Martin, Peter, Tolu, Seda , Casulo, Carla , Evens, Andrew M.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 518-518

10.1182/blood-2025-518 Get It

Abstract Background: Given a potential risk of extravasation with vesicants and irritants, central venous catheters (CVCs), such as port-a-cath or peripherally inserted central catheters (PICC), are commonly used for the administration of anthracycline-based chemotherapy. However, CVC placement can result in treatment delay, deep vein thrombosis (DVT), catheter malfunction, and added burdens (eg, financial, travel, etc), partly due to the need for regular flushing. Peripheral intravenous (PIV) access is often utilized in the academic setting with select frontline chemotherapy regimens. However, there is limited data reporting on the safety of PIV in this setting. This large, multicenter RWA evaluated the use and associated complications of PIV and CVC for administering CHOP- or ABVD-based chemotherapy in patients (pts) with lymphoma. Methods: We conducted a retrospective RWA across 8 U.S. centers among pts aged ≥18 years with non-Hodgkin lymphoma and Hodgkin lymphoma who were consecutively treated with ABVD or CHOP-based anthracycline chemotherapy via PIV or CVC access between 2010-2024. Choice of catheter placement was at the discretion of the pt's treating physician. Detailed baseline and safety data were collected. The primary outcome was extravasation; secondary outcomes included infiltration, DVT, cellulitis, erythema, and pain. Standard definitions of extravasation and other complications were used (Jackson-Rose J. CJON 2017). Rates of complications were compared via Fischer exact testing. Results: A total of 1,414 pts were included in the analysis: 790 in each arm (ie, PIV vs CVC). Of these, 624 were unique to each group, while 166 pts received chemotherapy via both modalities (PIV and CVC during the treatment course). Overall, 78.9% of pts completed all treatment as planned via PIV. Median age was 63 years (IQR 45–75) in the PIV group and 61 years (IQR 40–73) in the CVC group. Male sex comprised 57% vs 51%, ECOG 0–1 performance status was 83% vs 76%, and advanced-stage disease (stage III/IV) was present in 51% vs 62%, respectively. Lymphoma subtypes were comparable: DLBCL/high-grade/B-cell NOS (54.5% vs 56.1%), Hodgkin lymphoma (27.2% vs 27.5%), T-cell lymphoma (12.4% vs 6.6%), and indolent/mantle cell lymphoma (5.6% vs 6.7%). Among those receiving chemotherapy via CVC, 78.5% were treated through a port-a-cath and 21.5% via PICC. CHOP-based and ABVD-based regimens were administered to 68% and 32% of PIV pts, and 69.6% and 30.4% of CVC pts, respectively. A total of 4,084 (PIV) vs 3,859 (CVC) treatment cycles were delivered, corresponding to 4,347 (PIV) vs 4,884 (CVC) anthracycline infusion days. There was 1 documented case of extravasation in the CVC group and 2 suspected cases in the PIV group (p=0.9); for PIV, this translates to a per pt risk of 0.3% (or 0.05% of infusion days). The two PIV cases involved elderly women with DLBCL receiving CHOP. Both developed localized symptoms post-infusion and were treated conservatively (DMSO/warm compresses or dexrazoxane/ice), with full symptom resolution within 1 week and 1 day, respectively. No tissue or vascular injury occurred. Additionally, there were no significant differences between the PIV and CVC groups in the rates of induration/swelling (1.8% vs 2.0%, p=0.85), phlebitis/cellulitis (2.4% vs 2.4%, p=0.9), venous thromboembolism (VTE; 1.4% vs 2.0%, p=0.32), or erythema (3.8% vs 5.1%, p=0.27). Pain or tenderness at the infusion site (8.5% vs 2.9%, p=0.001) and infiltration (1.4 vs 0.13%, p=0.006) were more frequent in the PIV group. Chronic vascular complications related to prior VTE was slightly lower in the PIV group (0.13% vs 0.9%, p=0.06), but not significant. Additional details from a propensity score-matched analysis will be presented at the meeting. Conclusions: This is the largest known analysis to date evaluating the safety of PIV access for anthracycline-based chemotherapy in >1,500 lymphoma pts over a recent 15-year period, representing >9,000 total treatments with CHOP or ABVD. PIV access was found to be safe and associated with a low rate of serious complications. Moreover, extravasation was rare and there was not a significant difference observed between PIV and CVC use. While PIV use was associated with higher rates of local pain/tenderness and infiltration, the events were uncommon and self-limited. Despite the widespread default to CVC placement in many centers, these findings support the selective use of PIV in appropriate pts as elucidated here.
Description of three new Dryocola species: Dryocola mayonis sp. nov., Dryocola sharpae sp. nov.and Dryocola baronae sp. nov., isolated from human clinical samples
Mohammed, Hamidu T. , Koscianski, Christina, Gordy, Garrett G. , Johnson, Stephen , Patel, Robin , Patel, Robin

Mayo Clinic

International Journal of Systematic and Evolutionary Microbiology | December 2, 2025 | Volume: 75 | Issue: 12 | Pages: No page available

10.1099/ijsem.0.006986 | PMID 41329602 Get It

Three previously uncharacterized bacterial species, designated strains BD586 T , BD613 T and BD626 T , isolated from human clinical specimens, were identified at Mayo Clinic, Rochester, Minnesota, USA. Initial identification efforts using matrix-assisted laser desorption ionization-time-of-flight MS and partial 16S rRNA gene sequencing proved inconclusive. Comprehensive analysis involving phenotypic characterization, biochemical assays and whole-genome sequencing was undertaken. The isolates were Gram-negative, motile, facultatively anaerobic rods, occurring singly, in pairs and in short chains; BD613 T additionally formed small aggregates. The isolates tested positive for catalase and negative for oxidase. Their colonies appeared smooth, white, opaque and non-haemolytic. Growth was observed at 35 °C under aerobic, anaerobic and CO₂-enriched conditions, as well as in media with NaCl concentrations up to 10% and at pH 7-9. Phylogenetic relationships were inferred from core gene alignments, average nucleotide identity and digital DNA–DNA hybridization comparisons. Results confirmed the placement of BD586 T , BD613 T and BD626 T within the recently established Dryocola genus, while also indicating their novelty as distinct species. The major cellular fatty acids were C 16:0 and C 17:0 cyclo. Based on these findings, a formal description of three new species, Dryocola mayonis sp. nov. (type strain BD586 T =TSD 474 T , =NCTC 15089 T , =DSM 119465 T ), Dryocola sharpae sp. nov. (type strain BD613 T =TSD 475 T , =NCTC 15090 T , =DSM 119466 T ) and Dryocola baronae sp. nov. (type strain BD626 T =TSD 476 T , =NCTC 15091 T , =DSM 119479 T ), is proposed, and the genus description of Dryocola is emended to refine its genomic, morphological and chemotaxonomic boundaries.
Evaluation of platelet dense granules by transmission electron microscopy in healthy pediatric donors and pediatric patients with suspected platelet disorders
Greenmyer, Jacob R. , Howell, Kyle G., Johnson, Brandi, Drapeau, Noelle, Stromback, Lindsay R., Charlesworth, Jon E. , Gossman, Susan C., Gamez, Jeffrey D., Pruthi, Rajiv K. , Chen, Dong , Fischer, Karen M. , Warad, Deepti

Mayo Clinic

Platelets | November 28, 2025 | Volume: 36 | Issue: 1 | Pages: No page available

10.1080/09537104.2025.2590752 | PMID 41312564 Get It

Verschluss perianaler Fisteln bei Patient:innen unter Ustekinumab: Ergebnisse der Studien SEAVUE und STARDUST
Kuehbacher, T, Peyrin-Biroulet, L, Gasink, Christopher , Hoops, Timothy, Izanec, James , Nazar, M, Bravatà, Ivana, Lahaye, Marjolein, Sands, BE, Kuehbacher, Tanja, Peyrin‐Biroulet, Laurent , Panaccione, Remo , Ma, T, Irving, Peter Miles , Loftus, Edward V. , Danese, Silvio

Mayo Clinic

Zeitschrift für Gastroenterologie | November 25, 2025 | Volume: 60 | Issue: 08 | Pages: e425-e426

10.1055/s-0042-1754603 Get It

Physiologic Transition During Delayed Cord Clamping With Assisted Ventilation in Preterm Infants
Fang, Jennifer L. , Petroni, Gina R. , Law, Brenda Hiu Yan , Gorman, Terri, Leone, Tina A. , Thomas, Sumesh , Niermeyer, Susan, Kattwinkel, John, Duda, Gina M, Petroni, Gina R. , Varhegyi, Nikole, Thielen, Monika, Chisholm, Christian A., Liedl, Lavonne M., Amsbaugh, Amy, Niermeyer, Susan, Barry, John-S, Lamprecht, Amy, Berlinski, Carolyn S, Johnson, Jacque-Lynne F, Irvine, Leigh , Ciorogariu-Ivan, Anna-Maria, Byrne, Bobbi J., Underwood, Mark A. , Poulain, Francis R., Pesavento, Rosa R, Fray, Caroline , Athaide, Melba, Kane, Andrea F., Carlo, Waldemar A., Bulas, Dorothy , Fairchild, Karen D. , Strand, Marya L. , Warren, Jamie B. , Niermeyer, Susan, Niermeyer, Susan, Barry, James A, Rincon, Monica P. , Josephsen, Justin , Hawkins, Melissa, Ciorogariu‐Ivan, Anna‐Maria, Travers, Colm P. , Carlo, Waldemar A. , Kline‐Fath, Beth M. , Epelman, Mónica

Mayo Clinic

JAMA Network Open | November 24, 2025 | Volume: 8 | Issue: 11 | Pages: e2545258

10.1001/jamanetworkopen.2025.45258 | PMID 41284295 Get It

Importance Assisted ventilation during delayed cord clamping (DCC) may improve the physiologic transition of extremely preterm infants immediately after birth. Objective To determine whether assisted ventilation during 120 seconds of DCC was associated with reduced higher-level resuscitative interventions (intubation, chest compressions, or epinephrine administration) compared with DCC for 30 to 60 seconds followed by resuscitation. Design, Setting, and Participants This was a secondary analysis of the VentFirst randomized clinical trial that was conducted from September 2, 2016, through February 21, 2023, at 12 centers in the US and Canada. Infants born at 23 weeks 0 days’ to 28 weeks 6 days’ gestational age (GA) were included. Intervention Infants randomized to the intervention received either positive-pressure ventilation or continuous positive airway pressure from 30 to 120 seconds after birth, followed by umbilical cord clamping. Those randomized to control received 30 to 60 seconds of DCC followed by assisted ventilation. Main Outcomes and Measures The main outcome was the odds of higher-level resuscitative interventions in the delivery room (DR). Intention-to-treat analyses within 2 a priori cohorts (infants breathing well and not breathing well 30 seconds after birth) used the Cochran-Mantel-Haenszel method to estimate the odds ratios (ORs) of intervention vs control. Results All 570 infants enrolled in the trial were included. Infants had a median (IQR) GA of 26.6 (25.2-27.9) weeks and 273 (47.9%) were female. A total of 271 infants (47.5%) were assessed as not breathing well 30 seconds after birth (150 intervention and 121 control), and 299 (52.5%) were assessed as breathing well 30 seconds after birth (128 intervention and 171 control). In the not-breathing-well cohort, 146 infants (53.9%) were intubated in the DR, 4 received chest compressions (2 intervention and 2 control), and 1 received epinephrine (control). Intubation was less frequent in the intervention group (71 infants [47.3%] vs 75 infants [62.0%]; OR, 0.52; 95% CI, 0.30-0.89). When adjusted by GA strata at randomization, infants in the 26 to 28 weeks’ GA stratum who were in the intervention group were less likely to be intubated in the DR (18 of 79 infants [22.8%] vs 29 of 60 infants [48.3%]; OR, 0.32; 95% CI, 0.15-0.65). However, there was no difference in intubation rates for infants in the 23 to 25 weeks’ GA stratum (53 of 71 infants [74.7%] vs 46 of 61 infants [75.4%]; OR, 0.96; 95% CI, 0.44-2.12). Among infants breathing well at 30 seconds, 74 (24.7%) were intubated in the DR, and none received compressions or epinephrine. Intubation rates were similar between intervention and control in the breathing-well cohort. Conclusions and Relevance While the VentFirst trial did not find a difference in death or intraventricular hemorrhage, this secondary analysis found that assisted ventilation during DCC was associated with less intubation in the DR, primarily among infants born at 26 to 28 weeks’ gestation who were not breathing well 30 seconds after birth. Additional studies are needed before implementing assisted ventilation during DCC in clinical practice. Trial Registration ClinicalTrials.gov Identifier: NCT02742454
Central Venous Catheter Removal After Hematopoietic Stem Cell Transplant: A Review and Perspective
Cook, Eleanor , Rotz, Seth J. , Blacken, Robyn, Johnson, Darren, Alonso, Priscila Badia , French, Karis, Kent, Georgia , Huber, John , Hammoud, Miza Salim , Parker, Loretta , Kusnier, Katilyn , Lehmann, Leslie , Kapadia, Malika, Khera, Nandita , Nishitani, Miki , Craddock, John , Juckett, Mark, Maier, Steffani, O'Mathúna, Dónal, Phelan, Rachel , Young, Kylan, Jodele, Sonata , Snyder, Alana J. , Sampson, Megan , Dandoy, Christopher E. , Fitch, Taylor Jennelle , Badia, Priscila , Huber, John , Hammoud, Miza Salim , Myers, Kasiani , Craddock, John A , Jodele, Sonata , Schoettler, Michelle L , Sampson, Megan , Dandoy, Christopher E , Auletta, Jeffery J. , Bidgoli, Alan , French, Karis, Hartley, David , Maier, Steffani T. , O'Mathúna, Dónal, Nelson, Adam S. , Phelan, Rachel , Young, Kylan

Mayo Clinic

Pediatric Blood & Cancer | November 24, 2025 | Volume: 73 | Issue: 3 | Pages: No page available

10.1002/pbc.70001 | PMID 41277289 Get It

ABSTRACT Central venous catheters (CVCs) are a cornerstone of hematopoietic stem cell transplantation (HSCT), facilitating the delivery of chemotherapy, parenteral nutrition, medications, and blood products. Despite CVCs’ essential role, prolonged use can lead to complications such as increased risk of infection, thrombosis, mechanical issues, and psychosocial burden. However, the timing of CVC removal remains highly variable across institutions. Additionally, there are no standardized guidelines to balance the benefits of extended access against the risks of prolonged use. This narrative review examines the existing literature on CVC management post‐HSCT, highlighting key factors influencing the removal timing, such as patient characteristics, disease‐specific considerations, and institutional practices. The review emphasizes the urgent need for multi‐institutional research and standardized protocols to improve outcomes, reduce complications, and enhance the quality of care for HSCT patients.
A systematic review of objective return to sport criteria following hip arthroscopy for athletes
Scott, Parker, Hegarty, Cullen , Johnson, Andrew, Eischen, Joe, Nagelli, Christopher V. , Hevesi, Mario, Hegarty, Cullen J, Nagelli, Christopher, Hegarty, Cullen J., Johnson, Andrew, Eischen, Joe, Krych, Aaron J. , Hevesi, Mario , Johnson, Andrew

Mayo Clinic

Orthopedic Reviews | November 24, 2025 | Volume: 17 | Issue: No issue available | Pages: No page available

10.52965/001c.144729 | PMID 41306379 Get It

Purpose Hip arthroscopy is a minimally invasive procedure which has been increasingly used among athletes for several hip joint related pathologies as it allows for a faster recovery. However, objective return to sport criteria have not been described previously among this population. Objective To systematically review the literature to evaluate and describe the objective return-to-sport (RTS) criteria to release patients back to sport following hip arthroscopy. Methods We conducted a comprehensive literature search according to the PRISMA guidelines. Studies were included in the review if patients underwent a hip arthroscopy procedure and the study described criteria for their patients to RTS. Two independent reviewers selected studies for inclusion and extracted study characteristics and objective RTS criteria. Results Of the 306 that were a part of our original search, 6 studies fit our inclusion criteria. There were 250 athletes (average age: 26.1) and 263 hips which underwent hip arthroscopy surgery. Of these athletes, the cohort was on average 46.5% female and an average of 91.2% of athletes returned to sport about 6 months following surgery. The primary sports these athletes participated in were soccer, swimming, skiing/snowboarding, and hockey. The objective RTS measures that were generally described included sport specific tests, range-of-motion, hip strength, and performance-based criteria. Conclusion There are minimal studies who described objective RTS criteria to release patients back to sport following hip arthroscopy procedures. Sports specific tests, hip strength, and performance-based criteria were mentioned as objective criteria to release patients back to sport.
Developing CD8 T cells pre-alpha TCR rearrangement support development of a unique neuronal population in the thymus 3222
Hoyt-Miggelbrink, Alexandra, Moelker, Eliese , Johnson, Aaron J., Hoyt-Miggelbrink, Alexandra M. , Pfaller, Christian K. , Johnson, Aaron J., Ayasoufi, Katayoun

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1046 Get It

Abstract Description Peripheral nervous system innervation of various organs has been associated with the development and maintenance of the immune system. Various neurological insults including brain tumors induce thymic involution. Using flow cytometry and confocal microscopy, we identified a population of cells within the thymus that contained neuronal markers and morphology. Subsets expressed tyrosine hydroxylase, BIII tubulin and/or NeuN, distinguishing them from thymic epithelial cells. These cells do not express AIRE. Neuronal cell bodies and/or axonal processes were identified within the thymus. Using retrograde rabies vector neurotracers, we confirmed axonal connections and the identity of thymic neurons. To determine developmental T cell stages that support neuronal development, we evaluated RAG1/2 KO, TCRβ KO, TCRα KO, TCRγδ KO, CD4 KO, CD8 KO and OT-I and -II transgenics. RAG1/2 and TCRβ deficiency resulted in complete loss of thymic neurons. This is while TCRα KO, TCRγδ KO, CD4/8 KO and OT-II transgenics had normal thymic neuron development. Importantly, OT-I transgenics had a significant loss of neuron-like cells, indicating developing CD8 T cells pre-alpha arrangement control thymic innervation. Finally, introduction of healthy bone marrow into irradiated RAG KO mice can restore neuron development. To summarize, we describe a novel population of neuronal cells within the thymus that interact with developing thymocytes to establish optimal thymic innervation. Funding Sources R00NS117799 Topic Categories Neuroimmunology (NEUR)
Mitigating off target B cell transduction during in situ CAR T cell induction 3591
Hinson, Destin T , Keulen, Virginia P. Van , Hansen, Michael J. , Peña, Alvaro, Jenkins, James W. , Johnson, Aaron J. , Pease, Larry R. , Johnson, Aaron J. , Barry, Michael A.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1373 Get It

Abstract Description Therapeutic in situ chimeric antigen receptor (isCAR) T cells can be generated by targeting activated T cells within a lymph node (LN) with retroviruses encoding CARs. While isCAR T cells are successfully generated by intradermal LN priming using adenovirus encoding allogeneic MHC in all mouse lines tested, differences in emerging therapeutic peripheral isCAR T cells are found in a strain dependent manner. Potentially harmful off target retroviral transduction of B cells with CARs is observed within the targeted LN. Here we report the blockade of B cell transduction using anti-CD20 antibody B cell depletion with the introduction of anti-CD19 chimeric antigen receptors into the activated CD8+ T cells. Lymphocytes were analyzed in blood and LN following isCAR T cell generation. When B cells were depleted by systemic administration of anti-CD20 antibodies during isCAR T cell induction, >97.5% systemic depletion of B cells was achieved. Whereas very small numbers of CAR transduced B cells were found in the blood of mice not treated with anti-CD20, none were observed in animals systemically depleted of B cells. In contrast, CAR B cells persisted in the LN of local anti-CD20 treated animals. However, animals expressing dominant CD8+ isCAR T cell populations eliminated LN B cells expressing CARs by week two. Furthermore, systemic treatment of lymphoma in animals with anti-CD20 antibody complemented anti-CD19 isCAR T therapy while blocking off target B cell transduction. Funding Sources Mayo Clinic Ventures Mayo Clinic Graduate School of Biomedical Sciences Mayo Clinic Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Neutrophil-derived cell-free DNA mediates T cell dysfunction in glioblastoma 3237
Reesman, Rachael , Moelker, Eliese , Fain, Cori E. , Johnson, Aaron J. , Hoyt-Miggelbrink, Alexandra M. , Pfaller, Christian K. , Johnson, Aaron J. , Ayasoufi, Katayoun

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1057 Get It

Abstract Description Glioblastoma (GBM) is an aggressive brain cancer with poor survival. GBM patients have severe peripheral immunosuppression, including defective T cell responses. We showed that serum-derived factors were sufficient to inhibit T cell proliferation. This factor was nonsteroidal and larger than 100kDa. Mass-spectrometry and pathway analysis of suppressive serum implicated proteins involved in DNA response elements. We hypothesized that the suppressive factor is cell-free DNA (cfDNA). In support of this, serum levels of cfDNA are increased in glioma-bearing mice. Exposure to cfDNA from serum of glioma-bearing mice was sufficient to directly and potently inhibit T cell proliferation. Exposure to genomic DNA was not sufficient to induce proliferation defects in T cells, highlighting the unique features of cfDNA. Importantly, reducing cfDNA content using DNaseI was sufficient to partially restore proliferation capacity. We determined that the T cell proliferation defects were independent of AIM2 DNA sensing mechanisms, implicating a novel pathway of DNA sensing in T cells. Finally, to determine the origin of the cfDNA, we used methylation-seq and found that the majority of cfDNA originated from neutrophils, implicating NETosis. Together, we contend that cfDNA from neutrophils induces immunosuppressive effects in GBM. Our work highlights a potential role for targeting cfDNA, neutrophils, and/or NETs in order to reverse T cell dysfunction and improve patient outcomes in GBM. Funding Sources R00NS117799 Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)